Skip to main content
. Author manuscript; available in PMC: 2014 May 2.
Published in final edited form as: Cancer Chemother Pharmacol. 2012 May 24;70(1):83–94. doi: 10.1007/s00280-012-1878-y

Table 1.

Summary of model progression

Model description Baseline contamination CTM (h) OFV AIC
Base model
1 Allometric model on V1, V2, V3, CL, Q2, Q3 599 619
2 As model 1, 2 outliers from pilot excluded 583 603
3 As model 2, TVV1=θ1(AGE8.88)8θ 576 598
Contamination model
4 CTM = θ9 on CVL 1 parameter: fixed 0.486 ng/mL 557 583
5 CTM = θ9 · IPRED on CVL 1 parameter: proportional 0.192 529 555
6 CTM1 = θ9 · IPRED on CVL (no clearing)
CTM2 = θ10 · IPRED on CVL (with clearing)
2 parameters: proportional θ9 = 0.149
θ10 = 0.436
527 557
7 As model 5, CTM = (θ9 · exp(-Ke · TIME)) ·
IPRED on CVL
1 parameter: proportional,
declines with time
0.193 516 544

AIC Akaike’s information criteria, CL clearance, CTM contamination factor, CVL central venous line, DV observed concentration, IPRED individual predictions, Ke rate constant for change in contamination factor, OFV objective function value, Q2 and Q3 inter-compartmental clearance, TVV1 typical population value of volume of central compartment, V1 volume of central compartment, V2 and V3 volume of peripheral compartment